Lite Strategy Inc (LITS)
NASDAQ:LITS
Want to see LITS full AI Analyst Report?
Top Page
Lite Strategy
(NASDAQ:LITS)
Select Model
Select Model
Rating:44Neutral
Price Target:
$0.73
▼(-45.41% Downside)
Action:Reiterated
Date:06/06/26
The score is held down primarily by weak financial performance (zero revenue in recent periods, sizable losses, and ongoing cash burn) and bearish technicals (price below key moving averages with negative MACD and very weak RSI/Stoch). Valuation provides limited support because the company is loss-making (negative P/E) and no dividend yield is available.
Positive Factors
Low Leverage / Positive Equity
A zero-debt position with meaningful positive equity provides durable financial flexibility: it lowers default risk, offers runway to support operations while revenues are restored, and makes future capital raises less urgent or dilutive over the next several months.
Negative Factors
Revenue Collapse
A drop to zero reported revenue is a fundamental structural weakness: without recurring sales the asset-management business cannot cover operating costs or rebuild scale. Restoring consistent revenue is a prerequisite for sustainable margins and is uncertain in the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage / Positive Equity
A zero-debt position with meaningful positive equity provides durable financial flexibility: it lowers default risk, offers runway to support operations while revenues are restored, and makes future capital raises less urgent or dilutive over the next several months.
Read all positive factors
Lite Strategy (LITS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$25.22M
Dividend YieldN/A
Average Volume (3M)500.71K
Price to Earnings (P/E)―
Beta (1Y)0.86
Revenue GrowthN/A
EPS Growth57.61%
CountryUS
Employees4
SectorHealthcare
Sector Strength45
IndustryAsset Management - Cryptocurrency
Share Statistics
EPS (TTM)-9.13
Shares Outstanding34,025,200
10 Day Avg. Volume568,471
30 Day Avg. Volume500,711
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.78
Price to Sales (P/S)0.00
P/FCF Ratio-1.45
Enterprise Value/Market Cap1.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.22
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-3.71
Revenue Forecast (FY)$25.00M
Lite Strategy Business Overview & Revenue Model
Company Description
Lite Strategy, Inc. functions as a clinical-stage pharmaceutical firm, concentrating its efforts on creating innovative and distinct therapeutic solutions for cancer patients. This entity, which was previously known as MEI Pharma, Inc., officially...
Lite Strategy Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
48
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 65.30M | 48.82M | 40.70M | 34.80M |
| Gross Profit | 0.00 | -368.00K | 65.30M | 48.82M | 40.70M | 33.39M |
| EBITDA | -12.10M | -17.09M | 25.82M | -36.38M | -75.16M | -41.02M |
| Net Income | -60.82M | -15.95M | 17.78M | -31.84M | -54.45M | -41.31M |
Balance Sheet | ||||||
| Total Assets | 57.79M | 18.29M | 41.38M | 120.81M | 177.84M | 174.10M |
| Cash, Cash Equivalents and Short-Term Investments | 7.54M | 18.01M | 38.34M | 100.69M | 153.25M | 153.43M |
| Total Debt | 0.00 | 0.00 | 0.00 | 12.73M | 9.64M | 8.30M |
| Total Liabilities | 952.00K | 1.35M | 8.36M | 96.19M | 125.43M | 124.63M |
| Stockholders Equity | 56.84M | 16.93M | 33.02M | 24.62M | 52.41M | 49.47M |
Cash Flow | ||||||
| Free Cash Flow | -10.42M | -20.84M | -50.48M | -52.52M | -49.23M | -32.67M |
| Operating Cash Flow | -10.42M | -20.84M | -50.47M | -52.48M | -48.75M | -31.96M |
| Investing Cash Flow | -97.33M | 35.15M | 49.14M | 53.69M | 6.89M | 24.71M |
| Financing Cash Flow | 94.82M | 0.00 | -11.87M | -40.00K | 49.05M | 3.47M |
Lite Strategy Technical Analysis
Negative
1.33
Price Trends
1.08
Negative
1.12
Negative
1.65
Negative
Market Momentum
-0.11
Positive
24.94
Positive
16.82
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LITS, the sentiment is Negative. The current price of 1.33 is above the 20-day moving average (MA) of 0.94, above the 50-day MA of 1.08, and below the 200-day MA of 1.65, indicating a bearish trend. The MACD of -0.11 indicates Positive momentum. The RSI at 24.94 is Positive, neither overbought nor oversold. The STOCH value of 16.82 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LITS.
Lite Strategy Risk Analysis
Lite Strategy disclosed 29 risk factors in its most recent earnings report. Lite Strategy reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Lite Strategy Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $71.66M | -3.34 | -201.43% | ― | ― | 33.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $30.94M | -3.21 | -92.03% | ― | -100.00% | -170.04% | |
44 Neutral | $25.22M | -0.08 | -90.81% | ― | ― | 57.61% | |
44 Neutral | $357.61M | -4.76 | -118.24% | ― | 138.86% | 42.14% | |
39 Underperform | $12.81M | -0.16 | -191.12% | ― | ― | 38.53% |
* Healthcare Sector Average
LITS
Lite Strategy
0.74
-1.49
-66.77%
ABVC
ABVC BioPharma
1.19
-0.76
-38.97%
JSPR
Jasper Therapeutics
0.46
-5.17
-91.88%
PRLD
Prelude Therapeutics
4.49
3.52
362.89%
GANX
Gain Therapeutics
1.68
-0.06
-3.45%
ESLA
Estrella Immunopharma
1.06
0.11
11.58%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.